Peter Lin MD, CCFPDirector, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, Canada
Dr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.
Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.
DisclosuresDr. Lin has consulted with the following companies on Continuing Medical Education programs:
Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.
No clinical trials. No patents.
Recent Contributions to PracticeUpdate:
- Association of Daily Step Counts With All-Cause Mortality and Cardiovascular Events
- Pillars of Therapy to Slow Diabetic Nephropathy Progression
- Estimated Lifetime Gained With Cancer Screening Tests
- Prevalence and Predictors of Primary Nonadherence to Medications Prescribed in Primary Care
- Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas in Reducing the Risk of Major Adverse Cardiovascular Events
- Dupilumab for Patients With COPD With Type 2 Inflammation Indicated by Eosinophil Counts
- Association of Exposure to Extreme Temperature Events and Fine Particulate Matter With Myocardial Infarction–Related Mortality
- Association Between Serum 25-Hydroxyvitamin D Levels and the Risk of Colorectal Cancer
- Protective Effect of HDL-C Against Cardiovascular Disease
- Safety and Effectiveness of Self-Administered Intranasal Etripamil for Atrioventricular Nodal–Dependent Supraventricular Tachycardia